Unconfigured Ad

Collapse
X
 
  • Filter
  • Time
  • Show
Clear All
new posts
  • dnet
    Junior Member
    • Mar 2013
    • 1

    Getting raw counts needed for Deseq/EdgeR from TCGA RSEM files

    Hi,

    I wish to run DE analysis using DESeq or EdgeR on RNA-seq data downloaded from TCGA. I would like to use the Level 3 RNA-Seq data, which is already processed using RSEM.

    I wonder if I can use the column named "raw counts" in the RSEM un-normalized output as the raw read counts needed for the input for DESeq and EdgeR.

    For example, the column marked in bold in the file :

    Filename:
    unc.edu__IlluminaHiSeq_RNASeqV2__TCGA-A1-A0SB-01A-11R-A144-07__expression_rsem_gene.txt


    barcode gene_id raw_count scaled_estimate transcript_id
    TCGA-A1-A0SB-01A-11R-A144-07 ?|100130426 0 0 uc011lsn.1
    TCGA-A1-A0SB-01A-11R-A144-07 ?|100133144 34.05 1.23812E-06 uc010unu.1,uc010uoa.1


    Thanks !
    D. N.
  • mmuurr
    Junior Member
    • Oct 2013
    • 2

    #2
    i don't have an answer, but essentially am curious about the same point.
    i believe the TCGA Level 3 RNASeqv2 "unnormalized" data represents the 'raw' RSEM counts, and thus piping this input into edgeR would be fine... but perhaps i'm mistaken.
    one spot where i've seen conflicting opinions is on how edgeR handles non-integer based counts, which will be the case with the RSEM output.

    in a few test cases i've run, i haven't encountered any glaring errors, though i found a HUGE number of differentially expressed genes when comparing prostate cancer samples (both unmatched cases using exact tests and using a subset of matched cases using a GLM approach to handle the paired samples).
    at an FDR threshold of 0.05 (using B-H correction), nearly half the genome qualified as differentially expressed, which -- at first glance -- seemed high to me.

    Comment

    • Simon Anders
      Senior Member
      • Feb 2010
      • 995

      #3
      Are you sure that you used counts per gene, and not counts per transcript, as input? RSEM outputs the latter by default, but these are unsuitable (even in principle) for downstream analysis for differential expression testing. (If you don't know why, see my earlier posts on the subject.)

      Comment

      • mmuurr
        Junior Member
        • Oct 2013
        • 2

        #4
        yes, the counts are represented at the gene level for the publicly available TCGA RNASeqv2 (unnormalized) data.
        while i can't find the verbose output for the execution of their RNASeqv2 pipeline, my guess is that the RSEM mappings to transcripts are collapsed to the individual gene level by summing counts.
        so, there are ~20,000 genes represented in their "Level 3" files (lower levels, representing increasingly raw data -- e.g. the reads themselves -- are not all publicly available).

        as for the large number of differentially expressed genes, additional reading lends me to believe the non-integer counts do need to be rounded prior to edgeR analyses.
        (though even this rounding step has been the focus of some debate on the R/Bioconductor-help mailing list.)

        Comment

        • GenePool
          Registered Vendor
          • Mar 2014
          • 18

          #5
          Hi All,

          For what it's worth, we're committed to making this sort of data more freely available and usable by the community. In that spirt, we've included a freely available reference library of genomics data in our product, GenePool. This library happens to include the RNASeqV2 gene-level counts computed by the UNC pipeline that leveraged RSEM. We've also taken the time to extract and curate the sample-level metadata and make it easily available to researchers to subset the samples, and analyze the data accordingly. For more advanced users, you can easily just export out the counts and sample level metadata and get into more high-powered statistical analyses, that hopefully some day we just roll right back into the GenePool platform :-)

          Incidentally, we've also included the isoform-, splice-junction-, and exon-level counts as part of GenePool's premium content.

          If you're interested in learning more, please check out GenePool's growing genomics library, check out the following threads:

          Registered SEQanswers sponsors/vendors can post commercial content here. Please support our sponsors!

          Registered SEQanswers sponsors/vendors can post commercial content here. Please support our sponsors!


          We'd love to have your feedback on this effort.

          ------------------------------
          GenePool is making genomics data management, analysis, and sharing easier!
          Products @ www.stationxinc.com
          Last edited by GenePool; 11-23-2014, 10:03 PM.

          Comment

          Latest Articles

          Collapse

          • SEQadmin2
            Proteomic Platforms: How to Choose the Right Analytical Strategy to Improve Detection and Clinical Applications
            by SEQadmin2


            Proteomics platforms are evolving rapidly, with advances in mass spectrometry and affinity-based approaches expanding what researchers can detect and at what scale. As the field moves toward deeper proteome coverage and clinical applications, scientists face an increasingly complex landscape of tools. This article will explore how researchers are navigating these choices to find the right platform for their work.

            The systematic characterization of the human proteome has
            ...
            07-20-2026, 11:48 AM
          • SEQadmin2
            Advanced Sequencing Platforms Tackle Neuroscience’s Toughest Genomics Problems
            by SEQadmin2



            Genomics studies in neuroscience face a special challenge due to the brain’s complexity and scarcity of samples. Mapping changes in cell type and state using conventional next-generation sequencing methods remains challenging. Advances in technologies like single-cell sequencing, spatial transcriptomics, and long-read sequencing have opened the door to deeper studies of the brain and diseases like Alzheimer’s, amyotrophic lateral sclerosis (ALS), and schizophrenia.
            ...
            07-09-2026, 11:10 AM
          • SEQadmin2
            Cancer Drug Resistance: The Lingering Barrier to Rising Survival
            by SEQadmin2



            Cancer survival rates have significantly increased in the last few decades in the United States, reaching a combined 70% 5-year survival rate by 2021. Behind this number, there are years of research to find new therapies, drug targets, and early detection methods. But there is one core challenge that keeps slowing down these advances, and it’s about drug resistance.

            There is no single reason why many patients don’t respond to treatment as expected. Cancer is...
            07-08-2026, 05:17 AM

          ad_right_rmr

          Collapse

          News

          Collapse

          Topics Statistics Last Post
          Started by SEQadmin2, 07-24-2026, 12:17 PM
          0 responses
          30 views
          0 reactions
          Last Post SEQadmin2  
          Started by SEQadmin2, 07-23-2026, 11:41 AM
          0 responses
          23 views
          0 reactions
          Last Post SEQadmin2  
          Started by SEQadmin2, 07-20-2026, 11:10 AM
          0 responses
          213 views
          0 reactions
          Last Post SEQadmin2  
          Started by SEQadmin2, 07-13-2026, 10:26 AM
          0 responses
          79 views
          0 reactions
          Last Post SEQadmin2  
          Working...